These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17540684)

  • 1. Trends in secondary prevention of ischaemic heart disease in the UK 1994 2005: use of individual and combination treatment.
    DeWilde S; Carey IM; Richards N; Whincup PH; Cook DG
    Heart; 2008 Jan; 94(1):83-8. PubMed ID: 17540684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis.
    Hippisley-Cox J; Coupland C
    BMJ; 2005 May; 330(7499):1059-63. PubMed ID: 15879390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary prevention of coronary heart disease in older patients after the national service framework: population based study.
    Ramsay SE; Whincup PH; Lawlor DA; Papacosta O; Lennon LT; Thomas MC; Ebrahim S; Morris RW
    BMJ; 2006 Jan; 332(7534):144-5. PubMed ID: 16401630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach.
    Zeymer U; Jünger C; Zahn R; Bauer T; Bestehorn K; Senges J; Gitt A
    Curr Med Res Opin; 2011 Aug; 27(8):1563-70. PubMed ID: 21682553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug secondary prevention in postmenopausal women with ischemic heart disease.
    Zdrenghea D; Pop D; Sitar-Tăut A; Cebanu M; Zdrenghea V
    Rom J Intern Med; 2009; 47(1):41-5. PubMed ID: 19886068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
    Naderi SH; Bestwick JP; Wald DS
    Am J Med; 2012 Sep; 125(9):882-7.e1. PubMed ID: 22748400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals.
    Corp EV; Antoniou S; Wright PG; Khachi H; Vercaeren S; Wald DS
    QJM; 2009 Dec; 102(12):843-9. PubMed ID: 19828644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in prevalence of and prescribing for ischaemic heart disease in Ireland 1990-2002.
    Bennett K; Johnson H; Dack P; Shelley E; Feely J
    Ir J Med Sci; 2005; 174(3):4-8. PubMed ID: 16285330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
    Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP;
    Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
    Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
    JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The UK National Health Service: delivering equitable treatment across the spectrum of coronary disease.
    Hawkins NM; Scholes S; Bajekal M; Love H; O'Flaherty M; Raine R; Capewell S
    Circ Cardiovasc Qual Outcomes; 2013 Mar; 6(2):208-16. PubMed ID: 23481523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inequalities in prescribing of secondary preventative therapies for ischaemic heart disease in Ireland.
    Bennett KE; Williams D; Feely J
    Ir Med J; 2002 Jun; 95(6):169-72. PubMed ID: 12171263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
    Vermeer NS; Bajorek BV
    J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of use of antiplatelet drugs, beta blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in older patients with coronary artery disease in an academic nursing home.
    Joseph J; Koka M; Aronow WS
    J Am Med Dir Assoc; 2008 Feb; 9(2):124-7. PubMed ID: 18261706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function.
    Shah R; Wang Y; Foody JM
    Am J Cardiol; 2008 Jan; 101(2):217-22. PubMed ID: 18178410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome.
    Bezin J; Groenwold RH; Ali MS; Lassalle R; Robinson P; de Boer A; Moore N; Klungel OH; Pariente A
    Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):285-293. PubMed ID: 28124399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypotensive medication, statins, and the risk of glaucoma.
    Owen CG; Carey IM; Shah S; de Wilde S; Wormald R; Whincup PH; Cook DG
    Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3524-30. PubMed ID: 20130286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Few sex differences in the use of drugs for secondary prevention after stroke: a nationwide observational study.
    Sjölander M; Eriksson M; Glader EL
    Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):911-9. PubMed ID: 22069216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.